{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:05:56Z","timestamp":1770235556760,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen Cilag Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01591-z","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T07:33:05Z","timestamp":1763710385000},"page":"473-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Demographic and Clinical Characteristics, Patterns of Treatment, Quality of Life, and Resource Consumption Associated with the Management of Patients with Moderate to Severe Psoriasis in Clinical Practice in Spain: The SUMMER Project"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-6147","authenticated-orcid":false,"given":"Jaime","family":"Notario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Magdaleno-Tapial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Riera-Monroig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Novella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Cuervas-Mons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1591_CR1","volume":"93","author":"L Puig","year":"2019","unstructured":"Puig L, Ruiz de Morales JG, Dauden E, et al. Prevalence of ten immune-mediated inflammatory diseases (IMID) in Spain. Rev Esp Salud Publica. 2019;93:e201903013.","journal-title":"Rev Esp Salud Publica"},{"issue":"5","key":"1591_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ad.2013.12.008","volume":"105","author":"C Ferr\u00e1ndiz","year":"2014","unstructured":"Ferr\u00e1ndiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014;105(5):504\u20139.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1591_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0001-7310(09)71257-8","volume":"100","author":"L Puig","year":"2009","unstructured":"Puig L, Carrascosa JM, Daud\u00e9n E, et al. Directrices espa\u00f1olas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biol\u00f3gicos. Actas Dermo-Sifiliogr. 2009;100(5):386\u2013413.","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"4","key":"1591_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0001-7310(09)70821-X","volume":"100","author":"L Puig","year":"2009","unstructured":"Puig L, Bordas X, Carrascosa JM, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2009;100(4):277\u201386.","journal-title":"Actas Dermosifiliogr"},{"issue":"Supplement 2","key":"1591_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.13542","volume":"30","author":"E Dauden","year":"2016","unstructured":"Dauden E, Puig L, Ferrandiz C, Sanchez-Carazo JL, Hernanz-Hermosa JM. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2016;30(Supplement 2):1\u201318.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1591_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"JM Carrascosa","year":"2022","unstructured":"Carrascosa JM, Puig L, Belinch\u00f3n Romero I, et al. Practical update of the recommendations published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and general management of psoriasis with biologic therapy. Actas Dermosifiliogr. 2022;113(3):261\u201377.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"1591_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"issue":"12","key":"1591_CR8","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2014Update 2015\u2014Short version\u2014EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1591_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jbi.2017.07.012","volume":"73","author":"K Kreimeyer","year":"2017","unstructured":"Kreimeyer K, Foster M, Pandey A, et al. Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review. J Biomed Inform. 2017;73:14\u201329.","journal-title":"J Biomed Inform"},{"issue":"S 02","key":"1591_CR10","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1055\/s-0040-1716403","volume":"59","author":"A Wulff","year":"2020","unstructured":"Wulff A, Mast M, Hassler M, et al. Designing an openEHR-based pipeline for extracting and standardizing unstructured clinical data using natural language processing. Methods Inf Med. 2020;59(S 02):e64\u201378.","journal-title":"Methods Inf Med"},{"key":"1591_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2025.106049","volume":"204","author":"LB Elvas","year":"2025","unstructured":"Elvas LB, Almeida A, Ferreira JC. Natural language processing in medical text processing: a scoping literature review. Int J Med Inform. 2025;204:106049.","journal-title":"Int J Med Inform"},{"issue":"5","key":"1591_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clindermatol.2024.06.018","volume":"42","author":"J Shapiro","year":"2024","unstructured":"Shapiro J, Baum S, Pavlotzky F, et al. Application of a natural language processing artificial intelligence tool in psoriasis: a cross-sectional comparative study on identifying affected areas in patients\u2019 data. Clin Dermatol. 2024;42(5):480\u20136.","journal-title":"Clin Dermatol"},{"key":"1591_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251343579","volume":"17","author":"E Bilgin","year":"2025","unstructured":"Bilgin E. Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Ther Adv Musculoskelet Dis. 2025;17:1759720x251343579.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"1591_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35152","volume":"4","author":"AP Ambrosy","year":"2021","unstructured":"Ambrosy AP, Parikh RV, Sung SH, et al. A natural language processing-based approach for identifying hospitalizations for worsening heart failure within an integrated health care delivery system. JAMA Netw Open. 2021;4(11):e2135152.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1591_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cvdhj.2021.03.003","volume":"2","author":"MD Solomon","year":"2021","unstructured":"Solomon MD, Tabada G, Allen A, Sung SH, Go AS. Large-scale identification of aortic stenosis and its severity using natural language processing on electronic health records. Cardiovasc Digit Health J. 2021;2(3):156\u201363.","journal-title":"Cardiovasc Digit Health J"},{"key":"1591_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf224","author":"OA Alabas","year":"2025","unstructured":"Alabas OA, Evans I, McElhone K, et al. Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort. Clin Exp Dermatol. 2025. https:\/\/doi.org\/10.1093\/ced\/llaf224.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1591_CR17","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/jdv.15177","volume":"32","author":"E Dauden","year":"2018","unstructured":"Dauden E, Blasco AJ, Bonanad C, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(12):2058\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1591_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ad.2013.03.005","volume":"104","author":"E Dauden","year":"2013","unstructured":"Dauden E, Pujol RM, Sanchez-Carazo JL, et al. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study. Actas Dermo-Sifiliogr. 2013;104(9):807\u201314.","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"9","key":"1591_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ad.2011.03.014","volume":"102","author":"M Ara","year":"2011","unstructured":"Ara M, Perez A, Ferrando J. Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis [Spanish]. Actas Dermo-Sifiliogr. 2011;102(9):706\u201316.","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"10","key":"1591_CR20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1591_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10067-016-3464-x","volume":"36","author":"M Almirall","year":"2017","unstructured":"Almirall M, Rodriguez J, Mateo L, Carrascosa JM, Notario J, Gallardo F. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clin Rheumatol. 2017;36(2):439\u201343.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1591_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/1744666X.2019.1601014","volume":"15","author":"L Puig","year":"2019","unstructured":"Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019;15(6):589\u201397.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"1591_CR23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.17624","volume":"180","author":"A Al-Janabi","year":"2019","unstructured":"Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. Br J Dermatol. 2019;180(6):1348\u201351.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01591-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:26Z","timestamp":1770190826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01591-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01591-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jaime Notario has perceived consultancy\/speaker\u2019s honoraria and\/or participated in clinical trials sponsored by Abbvie, Almirall, Celgene, Gebro, IQVIA, Janssen, Leo Pharma, Lilly, MSD, Novartis and Pfizer. Jorge Magdaleno-Tapial has received consultancy\/speaker\u2019s honoraria and\/or travel grants and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Sanofi and UCB. Raquel Rivera acted as a consultant and\/or speaker for and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Abbvie, Almirall, Amgen, Boehringer, Bristol Myers Squibb, Janssen-Cilag, Leo Pharma, Lilly, Novartis, Pfizer and UCB. Josep Riera-Monroig has acted as a speaker and\/or consultant for and\/or participated in clinical trials from Almirall, Amgen, Abbvie, Novartis, Johnson\u00a0&\u00a0Johnson, UCB, LeoPharma, Pfizer, Eli Lilly, Boehringer, and Bristol Myers Squibb. Josep Riera-Monroig is an Editorial Board Member for\n                      Dermatology and Therapy\n                      . Josep Riera-Monroig was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Conrad Pujol has received grants and payments related to research, advice and training from Abbvie, Almirall, Amgen, Boehringer, Janssen-Cilag, Leo Pharma, Lilly, Novartis, Pfizer and UCB. Cynthia Novella and Manuel Cuervas-Mons are employees of Janssen. Pablo de la Cueva has received consultancy\/speaker\u2019s honoraria and\/or travel grants and\/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Johnson\u00a0&\u00a0Johnson, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by Ethics Committee of Hospital of Bellvitge, Barcelona (EPA028\/20), on January 1, 2021. Patient consent waiver for this retrospective study was obtained from this Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}